By Amber Jackson, RN, DCES Candidate
Weight management can be challenging for people using insulin.
While insulin is essential for people with type 1 diabetes and often necessary in type 2 diabetes, intensive insulin therapy has historically been associated with weight gain. Improved glucose utilization, reduced urinary calorie loss, insulin’s anabolic effects, and additional calorie intake to prevent or treat hypoglycemia may all contribute.
Emerging evidence suggests that Afrezza (Technosphere inhaled insulin) may offer a weight advantage compared with traditional subcutaneous rapid-acting insulin.
A multi-study evaluation presented at ADCES 2026 examined weight changes across three clinical trials—AFFINITY-1, STAT, and INHALE-3. Across all three studies, participants receiving inhaled insulin experienced essentially weight-neutral outcomes, while comparison groups using rapid-acting analog insulin or usual insulin therapy gained weight.
The differences were remarkably consistent:
- AFFINITY-1 (24 weeks): −0.4 kg with inhaled insulin vs. +0.9 kg with insulin aspart; treatment difference −1.3 kg (p=0.01).
- STAT (4 weeks): −0.2 kg vs. +0.8 kg; difference −1.0 kg (p=0.006).
- INHALE-3 (17 weeks): +0.1 kg vs. +1.4 kg; treatment difference −1.3 kg (p=0.03).
These findings are supported by broader research. A 2025 systematic review and meta-analysis of Technosphere insulin in type 1 diabetes found approximately 1.05 kg less weight gain compared with rapid-acting injectable insulin. An earlier systematic review similarly found about a 1.1 kg weight advantage with Technosphere inhaled insulin compared with subcutaneous insulin.
Why Might Afrezza Make a Difference?
Afrezza has a substantially different pharmacokinetic profile from injected rapid-acting insulin. Its absorption begins very rapidly, with measurable glucose-lowering effects occurring at approximately 12 minutes and effects returning toward baseline much sooner than conventional rapid-acting insulin. This shorter insulin exposure may potentially reduce late post-meal hypoglycemia and the need for additional carbohydrate intake to treat or prevent lows—one possible contributor to insulin-associated weight gain. However, the available studies establish an association with less weight gain, not the precise mechanism responsible.
The Takeaway
For people with diabetes who require mealtime insulin and are also working to manage their weight, Afrezza may provide a meaningful advantage by reducing the weight gain commonly associated with intensive insulin therapy. Current evidence should not be interpreted to mean that Afrezza is a weight-loss medication. Rather, studies consistently suggest a more weight-neutral profile and approximately 1 kg less weight gain compared with traditional rapid-acting insulin therapy—an important consideration when balancing glucose management with long-term metabolic health.
For more information about Afrezza, mealtime insulin options, or individualized diabetes management, contact the clinical team at Integrated Diabetes Services (IDS).
Our diabetes specialists can help determine which treatment strategies may best fit your individual needs and goals.
Resources
Martyn-Nemeth P, et al. Sleep Optimization to Improve Glycemic Targets in Adults With Type 1 Diabetes. Diabetes Care. 2026;49(7):1270-1279. doi:10.2337/dc26-0273.
